Rigorous evaluation through clinical testing is vital for advancing safe and effective therapies. Clinical trials in regenerative medicine assess how engineered tissues, cell therapies, and gene editing approaches perform in human subjects across a spectrum of conditions. These trials must balance innovation with patient safety, following tightly regulated frameworks to validate therapeutic efficacy and monitor adverse outcomes. From early-phase feasibility studies to large-scale randomized trials, each stage is shaped by complex logistics, including manufacturing standards, delivery methods, and biomarker development. Clinical trials in regenerative medicine also face unique challenges like variability in cell behavior, individualized responses, and long-term monitoring. Despite these hurdles, progress continues steadily, establishing confidence in regenerative approaches through evidence-based evaluation.
Title : Eliminating implants infections with nanomedicine: Human results
Thomas J Webster, Interstellar Therapeutics, United States
Title : Graphene, butterfly structures, and stem cells: A revolution in surgical implants
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, London NW1 0NH, United Kingdom
Title : Biodistribution and gene targeting in regenerative medicine
Nagy Habib, Imperial College London, United Kingdom
Title : Precision in cartilage repair: Breakthroughs in biofabrication process optimization
Pedro Morouco, Polytechnic of Leiria, Portugal
Title : AI-integrated high-throughput tissue-chip for brain aging
Kunal Mitra, Florida Tech, United States
Title : Assembly and stability of on-chip microvasculature
Kara E McCloskey, University of California, Merced, United States